CN1604780A - 在前痴呆状态中使用罗苏伐他汀 - Google Patents

在前痴呆状态中使用罗苏伐他汀 Download PDF

Info

Publication number
CN1604780A
CN1604780A CNA028253477A CN02825347A CN1604780A CN 1604780 A CN1604780 A CN 1604780A CN A028253477 A CNA028253477 A CN A028253477A CN 02825347 A CN02825347 A CN 02825347A CN 1604780 A CN1604780 A CN 1604780A
Authority
CN
China
Prior art keywords
dementia
rosuvastatin
cognitive
patient
risk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028253477A
Other languages
English (en)
Chinese (zh)
Inventor
H·巴森
T·皮塞
I·拉克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1604780A publication Critical patent/CN1604780A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
CNA028253477A 2001-10-19 2002-10-18 在前痴呆状态中使用罗苏伐他汀 Pending CN1604780A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE01035096 2001-10-19
SE0103509A SE0103509D0 (sv) 2001-10-19 2001-10-19 Rosuvastatin in pre demented states

Publications (1)

Publication Number Publication Date
CN1604780A true CN1604780A (zh) 2005-04-06

Family

ID=20285721

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028253477A Pending CN1604780A (zh) 2001-10-19 2002-10-18 在前痴呆状态中使用罗苏伐他汀

Country Status (19)

Country Link
US (1) US20060229321A1 (enExample)
EP (1) EP1446123A1 (enExample)
JP (1) JP2005505605A (enExample)
KR (1) KR20040058201A (enExample)
CN (1) CN1604780A (enExample)
AR (1) AR036891A1 (enExample)
BR (1) BR0213434A (enExample)
CA (1) CA2463597A1 (enExample)
CO (1) CO5580773A2 (enExample)
HU (1) HUP0401798A3 (enExample)
IL (1) IL161380A0 (enExample)
IS (1) IS7218A (enExample)
MX (1) MXPA04003631A (enExample)
NO (1) NO20041840L (enExample)
PL (1) PL369573A1 (enExample)
RU (1) RU2004112422A (enExample)
SE (1) SE0103509D0 (enExample)
WO (1) WO2003032995A1 (enExample)
ZA (1) ZA200402844B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7396927B2 (en) 2003-08-28 2008-07-08 Teva Pharmaceutical Industries Ltd. Process for preparation of rosuvastatin calcium
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
WO2005051921A1 (en) 2003-11-24 2005-06-09 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
CN1894221B (zh) 2003-12-02 2012-08-08 特瓦制药工业有限公司 用于表征罗苏伐他汀的参照标准品
WO2006017357A1 (en) 2004-07-13 2006-02-16 Teva Pharmaceutical Industries Ltd. A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
TWI345562B (en) 2005-02-22 2011-07-21 Teva Pharma Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
KR20070062996A (ko) 2005-08-16 2007-06-18 테바 파마슈티컬 인더스트리즈 리미티드 결정성 로수바스타틴 중간체
WO2012073256A1 (en) 2010-11-29 2012-06-07 Cadila Healthcare Limited Salts of rosuvastatin

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US7189703B2 (en) * 1998-01-09 2007-03-13 Intracell, Llc Treatment and diagnosis of alzheimer's disease
AR022462A1 (es) * 1999-02-06 2002-09-04 Astrazeneca Uk Ltd Uso de un agente que disminuye el colesterol
US20030100493A1 (en) * 2001-07-19 2003-05-29 Sol Weiss Sublingual use of inhibitors in the biosynthesis of cholesterol

Also Published As

Publication number Publication date
US20060229321A1 (en) 2006-10-12
EP1446123A1 (en) 2004-08-18
PL369573A1 (en) 2005-05-02
HUP0401798A3 (en) 2005-06-28
RU2004112422A (ru) 2005-04-10
BR0213434A (pt) 2004-11-09
HUP0401798A2 (hu) 2005-01-28
ZA200402844B (en) 2005-01-24
CA2463597A1 (en) 2003-04-24
SE0103509D0 (sv) 2001-10-19
WO2003032995A1 (en) 2003-04-24
IL161380A0 (en) 2004-09-27
JP2005505605A (ja) 2005-02-24
WO2003032995A8 (en) 2004-06-03
AR036891A1 (es) 2004-10-13
NO20041840L (no) 2004-05-05
CO5580773A2 (es) 2005-11-30
KR20040058201A (ko) 2004-07-03
MXPA04003631A (es) 2004-07-30
IS7218A (is) 2004-04-13

Similar Documents

Publication Publication Date Title
Haustein et al. Methotrexate in psoriasis: 26 years’ experience with low‐dose long‐term treatment
JP2001517617A (ja) 神経変性疾患の治療を目的としてapoeレベルを増加させる方法
Ohta et al. A prospective clinical study of theophylline safety in 3810 elderly with asthma or COPD
JP2019526544A (ja) 5−ht2bアゴニストの形成を阻害するための製剤およびその使用方法
EP2956443B1 (en) Hydantoins that modulate bace-mediated app processing
UA75614C2 (uk) Спосіб лікування гетерозиготної родинної гіперхолестеринемії розувастатином (zd-4522)
KR102547164B1 (ko) 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법
US20220133652A1 (en) A formulation for improving seizure control
JP2013521303A5 (enExample)
JP6466540B2 (ja) 多発性硬化症を治療するためのPPARγアゴニスト
Al-Ashwal et al. Identification and treatment of patients with homozygous familial hypercholesterolaemia: information and recommendations from a Middle East advisory panel
JP2024543053A (ja) 神経変性疾患の治療のための胆汁酸及びフェニルブチレート化合物の組合せ
TW201902471A (zh) 賈卡賓尼(gemcabene)、其醫藥上可接受之鹽、彼等之組成物及使用彼等之方法
US20060229321A1 (en) Rosuvastatin in pre demented states
US20230089715A1 (en) Masitinib for the treatment of a multiple sclerosis patient subpopulation
TW202410887A (zh) 用於治療肌肉萎縮性脊髓側索硬化症之方法及組成物
TWI242431B (en) Pharmaceutical compositions for treating pulmonary diseases
CN1547476A (zh) Atazanavir在hiv治疗中的用途
JP7668386B2 (ja) 1-(3-シアノ-1-イソプロピル-インドール-5-イル)ピラゾール-4-カルボン酸を含む薬学的組成物
AU2002347698A1 (en) Rosuvastatin in pre demented states
US20230390276A1 (en) Treatment of autoimmune diseases with a dihydroorotate hehydrogenase (dhodh) inhibitor
US20090062338A1 (en) Nitroxides for use in treating or preventing cardiovascular disease
Herd et al. Acute confusional state with postoperative intravenous cefazolin
JP2024505246A (ja) 神経変性認知障害を治療するための、コリンエステラーゼ阻害薬と四級アンモニウム抗ムスカリン剤との固定用量配合剤
JP2023181739A (ja) Cadasil患者を処置するための医薬組成物および方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication